168 related articles for article (PubMed ID: 8400346)
1. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
Gebbia V; Carreca I; Testa A; Valenza R; Curto G; Cannata G; Borsellino N; Latteri MA; Cipolla C; Florena M
Anticancer Drugs; 1993 Aug; 4(4):443-5. PubMed ID: 8400346
[TBL] [Abstract][Full Text] [Related]
2. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
Topkan E; Karaoglu A
Oncology; 2006; 71(5-6):354-60. PubMed ID: 17873499
[TBL] [Abstract][Full Text] [Related]
3. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
Cascinu S; Fedeli A; Fedeli SL; Catalano G
J Clin Oncol; 1993 Jan; 11(1):148-51. PubMed ID: 8418225
[TBL] [Abstract][Full Text] [Related]
4. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Barbounis V; Koumakis G; Vassilomanolakis M; Demiri M; Efremidis AP
Support Care Cancer; 2001 Jun; 9(4):258-60. PubMed ID: 11430421
[TBL] [Abstract][Full Text] [Related]
5. Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial.
Garcia Compean D; Ramos Jimenez J; Guzman de la Garza F; Saenz C; Maldonado H; Barragan RF; Michel H
AIDS; 1994 Nov; 8(11):1563-7. PubMed ID: 7848592
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients.
Geller RB; Gilmore CE; Dix SP; Lin LS; Topping DL; Davidson TG; Holland HK; Wingard JR
Am J Hematol; 1995 Nov; 50(3):167-72. PubMed ID: 7485077
[TBL] [Abstract][Full Text] [Related]
7. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
Rosenoff S
Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Hoff PM; Saragiotto DF; Barrios CH; del Giglio A; Coutinho AK; Andrade AC; Dutra C; Forones NM; Correa M; Portella Mdo S; Passos VQ; Chinen RN; van Eyll B
J Clin Oncol; 2014 Apr; 32(10):1006-11. PubMed ID: 24516038
[TBL] [Abstract][Full Text] [Related]
9. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.
Cascinu S; Fedeli A; Fedeli SL; Catalano G
Eur J Cancer; 1992; 28(2-3):482-3. PubMed ID: 1591068
[TBL] [Abstract][Full Text] [Related]
10. Octreotide in the treatment of severe chemotherapy-induced diarrhea.
Zidan J; Haim N; Beny A; Stein M; Gez E; Kuten A
Ann Oncol; 2001 Feb; 12(2):227-9. PubMed ID: 11300329
[TBL] [Abstract][Full Text] [Related]
11. [Management of chemotherapy induced diarrhea].
Schultz M; Schölmerich J; Kullmann F
Z Gastroenterol; 2004 Jun; 42(6):527-38. PubMed ID: 15190449
[TBL] [Abstract][Full Text] [Related]
12. High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients.
Cascinu S; Bichisao E; Amadori D; Silingardi V; Giordani P; Sansoni E; Luppi G; Catalano V; Agostinelli R; Catalano G
Support Care Cancer; 2000 Jan; 8(1):65-7. PubMed ID: 10650901
[TBL] [Abstract][Full Text] [Related]
13. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
Petrelli NJ; Rodriguez-Bigas M; Rustum Y; Herrera L; Creaven P
Cancer; 1993 Sep; 72(5):1543-6. PubMed ID: 8348489
[TBL] [Abstract][Full Text] [Related]
14. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
Mystakidou K; Katsouda E; Tsilika E; Smyrniotis V; Vassiliou I; Tsiatas M; Vlahos L
Anticancer Res; 2006; 26(3B):2325-8. PubMed ID: 16821610
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of diarrhea with loperamide in palliative medicine. A systematic review].
Pastrana T; Meißner W
Schmerz; 2013 Apr; 27(2):182-9. PubMed ID: 23475156
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, double-blind, randomized comparison of wood creosote, the principal active ingredient of Seirogan, an herbal antidiarrheal medication, and loperamide in adults with acute nonspecific diarrhea.
Kuge T; Shibata T; Willett MS
Clin Ther; 2004 Oct; 26(10):1644-51. PubMed ID: 15598481
[TBL] [Abstract][Full Text] [Related]
17. Octreotide in the management of diarrhea induced by graft versus host disease.
Ippoliti C; Neumann J
Oncol Nurs Forum; 1998 Jun; 25(5):873-8. PubMed ID: 9644703
[TBL] [Abstract][Full Text] [Related]
18. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy.
Wasserman E; Hidalgo M; Hornedo J; Cortés-Funes H
Bone Marrow Transplant; 1997 Nov; 20(9):711-4. PubMed ID: 9384471
[TBL] [Abstract][Full Text] [Related]
19. Loperamide: a new antidiarrheal agent in the treatment of chronic diarrhea.
Galambos JT; Hersh T; Schroder S; Wenger J
Gastroenterology; 1976 Jun; 70(6):1026-9. PubMed ID: 773735
[TBL] [Abstract][Full Text] [Related]
20. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin.
Cascinu S; Fedeli A; Fedeli SL; Catalano G
Oncology; 1994; 51(1):70-3. PubMed ID: 8265106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
